Since 2004, oncogene addiction has been demonstrated in terms of DNA mutations in the EGFR (exon 19–21); B-RAF (V600E); MET (exon 14 skip mutations); intragenic insertions in EGFR and ERB-B2 (exon 20); or fusion rearrangements in ALK, ROS1, RET, NTRK, and NRG1 in patients with lung adenocarcinoma. The gene discussed is EGFR; the disease is lung adenocarcinoma.